美国生物安全法案“搁浅”“药明系”CXO企业成功上岸了吗?

投资者网
14 Dec 2024

全文2628字,阅读约需8分钟,帮我划重点划重点01美国生物安全法案未能列入2025财年国防授权法案,药明系CXO企业迎来新的局面。0212月9日,药明系大涨,药明生物涨超13%,药明康德H股涨近12%,药明康德A股涨近8%。03由于美国立法程序需要耗费很长时间,生物安全法案一直悬而未决,对药明系及其他具有重大海外收入敞口的中国CRO/CDMO公司是一个积极的进展。04与此同时,药明系企业已经开始...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10